ARKVX — ARK Venture Fund

Is ARKVX overbought or oversold? Here is the current MarketMoodz read.

FUND

Oversold As of November 17, 2026

ARK Venture Fund (ARKVX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The FUND name last closed at $59.25. The rating moved from Neutral to Oversold on November 1, 2026.

See all oversold FUND stocks →

AI analysis

ARK Venture Fund offers targeted exposure to high-growth, innovation-driven companies and benefits from an active, thematic approach that can outperform in risk-on environments. Short-term upside is supported by current market sentiment favoring growth and potential positive news flow from holdings. However, the strategy carries above-average volatility, concentration risk, and sensitivity to macro shifts and valuation compression. Investors should weigh the fund’s potential for outsized gains against the probability of meaningful drawdowns during market stress.

Key factors

  • Concentrated exposure to disruptive and early-stage growth companies that can deliver outsized returns in risk-on environments
  • Active management with a high-conviction, thematic investment approach focused on innovation (AI, genomics, fintech, electrification)
  • Current market tone favoring growth and earnings-driven positioning, which can support short-term performance
  • Retail interest and ARK-branded products often generate incremental flows in bullish equity markets
  • Potential for strong upside from positive earnings, product adoption, or breakthrough announcements among portfolio holdings
  • Diversification across multiple innovation themes within a single vehicle provides broad exposure for growth-oriented investors

Risks

  • High concentration and single-theme risk: large position sizes in a limited number of high-volatility names
  • Elevated market volatility and a shift to risk-off or rising real rates would disproportionately hurt performance
  • Liquidity and redemption risk in stressed markets for holdings in smaller private or thinly traded public companies
  • Valuation sensitivity: many holdings trade at premium multiples that require rapid growth to justify prices
  • Regulatory or technological setbacks to core innovation themes (e.g., biotech approvals, platform regulation)
  • Lack of recent fund-specific filings or sector data in the provided inputs increases information uncertainty

See today's live rating, score and targets

Members see the live hourly rating for ARKVX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.